CollPlant Biotechnologies Unveils Inaugural ESG and Sustainability Report
CollPlant Biotechnologies (Nasdaq: CLGN) has released its first Environmental, Social and Corporate Governance (ESG) and Sustainability Report for 2023. The report outlines the company's initiatives to adopt an ESG strategy focused on high-impact areas. CollPlant aims to enhance plant-based production, reduce emissions, and deliver safe medical solutions.
The strategy is built on three pillars: Impact on the Planet, Impact on People, and Impact on Business Conduct. CollPlant's innovative rhCollagen technology eliminates the need for animal-derived collagen, promoting more ethical and sustainable practices. The company is committed to accelerating the transition to a low-carbon footprint world and enhancing its corporate ESG practices.
CEO Yehiel Tal emphasized that CollPlant's overall strategy is driven by its vision to lead in regenerative medicine and improve global health with its collagen technology. The report serves as a foundation for sharing the company's journey, ambitions, and steps towards a sustainable future in regenerative and aesthetic medicine.
CollPlant Biotechnologies (Nasdaq: CLGN) ha pubblicato il suo primo Rapporto Ambientale, Sociale e di Governance (ESG) e di Sostenibilità per il 2023. Il rapporto delinea le iniziative dell'azienda per adottare una strategia ESG focalizzata su aree ad alto impatto. CollPlant ha l'obiettivo di migliorare la produzione basata su piante, ridurre le emissioni e fornire soluzioni mediche sicure.
La strategia si basa su tre pilastri: Impatto sul Pianeta, Impatto sulle Persone e Impatto sulla Condotta Aziendale. La tecnologia innovativa rhCollagen di CollPlant elimina la necessità di collagene derivato da animali, promuovendo pratiche più etiche e sostenibili. L'azienda è impegnata ad accelerare la transizione verso un mondo a bassa impronta di carbonio e a migliorare le sue pratiche ESG aziendali.
Il CEO Yehiel Tal ha sottolineato che la strategia complessiva di CollPlant è guidata dalla sua visione di essere leader nella medicina rigenerativa e di migliorare la salute globale con la sua tecnologia del collagene. Il rapporto serve come base per condividere il percorso, le ambizioni e i passi dell'azienda verso un futuro sostenibile nella medicina rigenerativa e estetica.
CollPlant Biotechnologies (Nasdaq: CLGN) ha lanzado su primer Informe de Medio Ambiente, Social y Gobernanza (ESG) y Sostenibilidad para 2023. El informe describe las iniciativas de la empresa para adoptar una estrategia ESG centrada en áreas de alto impacto. CollPlant busca mejorar la producción basada en plantas, reducir emisiones y ofrecer soluciones médicas seguras.
La estrategia se basa en tres pilares: Impacto en el Planeta, Impacto en las Personas y Impacto en la Conducta Empresarial. La innovadora tecnología rhCollagen de CollPlant elimina la necesidad de colágeno derivado de animales, promoviendo prácticas más éticas y sostenibles. La empresa está comprometida a acelerar la transición hacia un mundo con baja huella de carbono y a mejorar sus prácticas ESG corporativas.
El CEO Yehiel Tal enfatizó que la estrategia general de CollPlant está impulsada por su visión de liderar en medicina regenerativa y mejorar la salud global con su tecnología de colágeno. El informe sirve como base para compartir el viaje, las ambiciones y los pasos de la empresa hacia un futuro sostenible en medicina regenerativa y estética.
CollPlant Biotechnologies (Nasdaq: CLGN)는 2023년 첫 번째 환경, 사회 및 지배구조(ESG) 및 지속 가능성 보고서를 발표했습니다. 이 보고서는 고임팩트 분야에 초점을 맞춘 ESG 전략을 채택하기 위한 회사의 이니셔티브를 설명합니다. CollPlant는 식물 기반 생산을 향상하고, 배출가스를 줄이며, 안전한 의료 솔루션을 제공하는 것을 목표로 하고 있습니다.
이 전략은 세 가지 기둥에 기반하고 있습니다: 지구에 대한 영향, 사람에 대한 영향, 비즈니스 행동에 대한 영향. CollPlant의 혁신적인 rhCollagen 기술은 동물에서 유래한 콜라겐의 필요성을 없애 더 윤리적이고 지속 가능한 관행을 촉진합니다. 이 회사는 저탄소 발자국 세계로의 전환을 가속화하고 자사의 ESG 관행을 개선하기 위해 최선을 다하고 있습니다.
CEO Yehiel Tal은 CollPlant의 전반적인 전략이 재생 의학 분야에서 선도하고 콜라겐 기술로 글로벌 건강을 개선하겠다는 비전에 의해 추진된다고 강조했습니다. 이 보고서는 재생 의학 및 미용 의학에서 지속 가능한 미래를 향한 회사의 여정, 포부 및 단계를 공유하는 기초 역할을 합니다.
CollPlant Biotechnologies (Nasdaq: CLGN) a publié son premier Rapport sur l'Environnement, le Social et la Gouvernance (ESG) ainsi que sur la Durabilité pour 2023. Le rapport décrit les initiatives de l'entreprise pour adopter une stratégie ESG axée sur des domaines à fort impact. CollPlant vise à améliorer la production à base de plantes, à réduire les émissions et à fournir des solutions médicales sûres.
La stratégie repose sur trois piliers : Impact sur la Planète, Impact sur les Personnes et Impact sur la Conduite Commerciale. La technologie innovante rhCollagen de CollPlant élimine le besoin de collagène d'origine animale, favorisant des pratiques plus éthiques et durables. L'entreprise s'engage à accélérer la transition vers un monde à faible empreinte carbone et à améliorer ses pratiques ESG.
Le PDG Yehiel Tal a souligné que la stratégie globale de CollPlant est guidée par sa vision de devenir un leader en médecine régénérative et d'améliorer la santé mondiale grâce à sa technologie du collagène. Le rapport sert de base pour partager le parcours, les ambitions et les étapes de l'entreprise vers un avenir durable dans la médecine régénérative et esthétique.
CollPlant Biotechnologies (Nasdaq: CLGN) hat seinen ersten Umwelt-, Sozial- und Governance-(ESG) sowie Nachhaltigkeitsbericht für 2023 veröffentlicht. Der Bericht beschreibt die Initiativen des Unternehmens zur Einführung einer ESG-Strategie, die sich auf Bereiche mit hoher Wirkung konzentriert. CollPlant zielt darauf ab, die pflanzenbasierte Produktion zu verbessern, Emissionen zu reduzieren und sichere medizinische Lösungen bereitzustellen.
Die Strategie basiert auf drei Säulen: Einfluss auf den Planeten, Einfluss auf Menschen und Einfluss auf unternehmerisches Handeln. Die innovative rhCollagen-Technologie von CollPlant beseitigt die Notwendigkeit für tierisches Kollagen und fördert ethischere und nachhaltigere Praktiken. Das Unternehmen verpflichtet sich, den Übergang zu einer Welt mit geringem Kohlenstoffausstoß zu beschleunigen und seine unternehmerischen ESG-Praktiken zu verbessern.
CEO Yehiel Tal betonte, dass die Gesamtstrategie von CollPlant durch die Vision geprägt ist, im Bereich der regenerativen Medizin zu führen und die globale Gesundheit mit seiner Kollagentechnologie zu verbessern. Der Bericht dient als Grundlage, um den Weg, die Ambitionen und die Schritte des Unternehmens in Richtung einer nachhaltigen Zukunft in der regenerativen und ästhetischen Medizin zu teilen.
- None.
- None.
REHOVOT,
The Company's first report details the initiatives that CollPlant has taken to adopt an ESG strategy with a focus on the pillars that represent the areas with the highest impact. In aligning the Company's operations with its ethical commitments, the Company plans to enhance plant-based production, reduce emissions, and deliver safe and reliable medical solutions. The report reflects CollPlant's wide commitment to fostering environmental sustainability and enhancing human health, as well as advancing social and corporate governance objectives that contribute to the Company's impact.
Yehiel Tal, Chief Executive Officer of CollPlant Biotechnologies, stated, "We've established a corporate sustainability strategy with clear targets in key areas that we believe are crucial to our stakeholders. I would like to emphasize that our overall strategy is driven by our vision to lead in regenerative medicine and improve global health with our innovative collagen technology. Our inaugural ESG report lays the foundation for sharing our journey, ambitions, and the tangible steps we are taking towards a sustainable future."
CollPlant's strategy is anchored in three pillars—Impact on the Planet, Impact on People, and Impact on Business Conduct—all of which guide its efforts and form the core of the Company's sustainability reporting.
Mr. Tal continued, "We are deeply committed to accelerating the transition to a low-carbon footprint world and plan to continue to make progress in enhancing our corporate ESG practices. Inherently, our business is designed around creating less environmental impact on the planet and our ESG and Sustainability Report details the various ways we contribute to the welfare of the habitats and communities we serve. Our innovative rhCollagen eliminates the need for traditional animal-derived collagen sources, thereby reducing the environmental strain associated with conventional collagen production methods. This promotes more ethical and sustainable practices."
Click here to read the full sustainability report.
About CollPlant
CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.
In 2021 CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market.
For more information about CollPlant, visit collplant.com.
Forward-Looking Statements
This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's objectives plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate.
Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the Company's history of significant losses, its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; the Company's expectations regarding the costs and timing of commencing and/or concluding pre-clinical and clinical trials with respect to breast implants, tissues and organs which are based on its rhCollagen based BioInk and other products for medical aesthetics, and specifically the Company's ability to initiate its next large-animal study for its breast implants in a timely manner, or at all; the Company's or it strategic partners' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen based bioink and medical aesthetics products including but not limited to acceptance of an application for marketing authorization review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the Company's rhCollagen based products, in 3D Bioprinting and medical aesthetics; the Company's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third party distributors and resellers; the Company's ability to establish and maintain strategic partnerships and other corporate collaborations, including its partnership with AbbVie and its ability to continue to receive milestone and royalties payments under the AbbVie agreement; the Company's reliance on third parties to conduct some or all aspects of its product development and manufacturing; the scope of protection the Company is able to establish and maintain for intellectual property rights and the Company's ability to operate its business without infringing the intellectual property rights of others; current or future unfavorable economic and market conditions and adverse developments with respect to financial institutions and associated liquidity risk; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the Company operates, including, with respect to the ongoing war in
Contacts
CollPlant:
Eran Rotem
Deputy CEO & CFO
Tel: + 972-73-2325600
Eran@collplant.com
Investors:
LifeSci Advisors
Dan Ferry
daniel@lifesciadvisors.com
Photo: https://mma.prnewswire.com/media/2470615/CollPlant.jpg
Logo: https://mma.prnewswire.com/media/2217353/CollPlant_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/news-releases/collplant-biotechnologies-unveils-inaugural-esg-and-sustainability-report-302208475.html
SOURCE CollPlant
FAQ
What is the main focus of CollPlant Biotechnologies' first ESG and Sustainability Report?
What are the three pillars of CollPlant's sustainability strategy?
How does CollPlant's rhCollagen technology contribute to sustainability?
What is CollPlant's commitment regarding carbon footprint?
When did CollPlant release its first ESG and Sustainability Report?
